natgillin/translations-raw huggingface dataset:
With severe intoxication, serious disturbances of the acid-base equilibrium occur.
Pri hudi zastrupitvi se pojavijo resne motnje acido-baznega ravnotežja.
• severe abdominal pain with or without back pain
• huda bolečina v trebuhu z ali brez bolečine v hrbtu,
The incidence of severe cases was similar for clopidogrel and ASA.
Incidenca hujših primerov je bila podobna za klopidogrel in ASA.
If acetylsalicylic acid is used by a woman attempting to conceive, or until the 24th amenorrhea week (5th month of pregnancy), the dose should be kept as low and duration of treatment as short as possible.
Če acetilsalicilno kislino uporablja ženska, ki poskuša zanositi, ali do 24. tedna amenoreje (5. mesec nosečnosti), mora biti odmerek čim manjši, zdravljenje pa čim krajše.
Uricosurics (benzbromarone, probenecid, sulfinpyrazone)
Urikozuriki (benzbromaron, probenecid, sulfinpirazon)
It is unknown whether ASA alters fertility.
Ni znano, če ASA vpliva na plodnost.
• generalised allergic reactions (for example, overall sensation of heat with sudden general discomfort until fainting)
• splošne alergijske reakcije (na primer, splošni občutek toplote z nenadnim nelagodjem do nezavesti),
The influence of CYP2C19 genotype on clinical outcomes in patients treated with clopidogrel has not been evaluated in prospective, randomised, controlled trials.
Vpliv genotipa CYP2C19 na klinične izide pri bolnikih, zdravljenih s klopidogrelom, ni bil ocenjen v prospektivnih, randomiziranih, kontroliranih raziskavah.
Haemodialysis is the preferred treatment for severe intoxication.
Hemodializa je izbrani način zdravljenja hude zastrupitve.
- cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary
- kardiopulmonalnim toksičnim učinkom (s prezgodnjim zaprtjem arterioznega duktusa in
The European Medicines Agency has waived the obligation to submit the results of studies with the combination of clopidogrel/acetylsalicylic acid in all subsets of the paediatric population in the treatment of coronary atherosclerosis (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od obveznosti po predložitvi rezultatov študij kombinacije klopidogrela/acetilsalicilne kisline pri vseh podskupinah pediatrične populacije za zdravljenje koronarne ateroskleroze (glejte poglavje 4.2 za informacije o pediatrični uporabi).
Thus, the results from this subset are in line with the overall trial results.
Pri tej podskupini bolnikov so rezultati v skladu s celotnimi rezultati študije.
In poor metabolisers, active metabolite exposure was decreased by 63-71% compared to extensive metabolisers.
Pri slabih metabolizatorjih je bila izpostavljenost aktivnemu presnovku za 63 do 71 % manjša kot pri obsežnih metabolizatorjih.
The combination of clopidogrel/acetylsalicylic acid should not be used during the first two trimesters of pregnancy unless the clinical condition of the woman requires treatment with clopidogrel/ASA.
Kombinacije klopidogrela/acetilsalicilne kisline se ne sme uporabljati v prvih dveh tromesečjih nosečnosti, razen če klinično stanje nosečnice ne zahteva terapije s klopidogrelom/ASA.
Patients should be told about the signs and symptoms of GI undesirable effects and what steps to take if they occur (see section 4.8).
Bolnike je treba seznaniti z znaki in simptomi neželenih gastrointestinalnih učinkov ter kako naj ukrepajo, če se le-ti pojavijo (glejte poglavje 4.8).
Patients should inform physicians and dentists that they are taking the combination of clopidogrel/acetylsalicylic acid before any surgery is scheduled and before any new medicinal product is taken.
Bolniki morajo obvestiti zdravnika in zobozdravnika, da jemljejo kombinacijo klopidogrela/ acetilsalicilne kisline, pred vsakim načrtovanim kirurškim posegom in preden vzamejo katerokoli novo zdravilo.
Alkalising of the urine (250 mmol sodium bicarbonate for 3 hours) while monitoring the urine pH is indicated.
Indicirana je alkalizacija urina (250 mmol natrijevega bikarbonata, in sicer 3 ure) ob nadzorovanju pH urina.
Reye's Syndrome is a very rare disease which can be fatal.
Reyev sindrom je zelo redka bolezen, ki je lahko smrtna.
Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole.
Manj izrazita zmanjšana izpostavljenost presnovkov je bila opažena pri pantoprazolu ali lanzoprazolu.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation:
Datum prve odobritve:
• Hypersensitivity to the active substances or to any of the excipients listed in section 2 or section
• preobčutljivosti na zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 2 ali
Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic (PK) interactions.
Druga zdravila: Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi preučili potencial za farmakodinamične in farmakokinetične interakcije.
The safety and efficacy of clopidogrel/acetylsalicylic acid in children and adolescents under 18 years old have not been established.
Varnost in učinkovitost zdravila Klopidogrel/acetilsalicilna kislina Teva pri otrocih in mladostnikih mlajših od 18 let nista bili ugotovljeni.
• if you have a history of asthma or allergic reactions including allergy to any medicine used to
• če ste v imeli v preteklosti astmo ali alergijske reakcije, vključno z alergijo na katerokoli
This is linked to the way your medicine works as it prevents the ability of blood clots to form.
To je povezano z načinom delovanja zdravila, saj le-to preprečuje strjevanje krvi.
The elimination half-life of the main circulating (inactive) metabolite was 8 hours after single and repeated administration.
Razpolovni čas izločanja glavnega (neaktivnega) krožečega presnovka je bil 8 ur po enkratnem in večkratnem dajanju.
Caution is required because ASA may inhibit the effect of uricosuric agents through competitive elimination of uric acid.
Potrebna je previdnost, saj ASA lahko zavre učinek urikozuričnih zdravil s kompetitivno eliminacijo sečne kisline.
Where elective surgery is being considered, the need for dual antiplatelet therapy should be reviewed and consideration given to the use of a single antiplatelet agent.
Če je predvidena elektivna operacija, je treba potrebo po dvotirnem antiagregacijskem zdravljenju ponovno pretehtati ter razmisliti o uporabi samo enega antiagregacijskega zdravila.
Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese.
Objavljene pogostnosti genotipa slabega metabolizatorja s CYP2C19 so približno 2% pri belcih, 4% pri črncih in 14% pri Kitajcih.
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel plus ASA group and 363 (5.8%) in the ASA group].
Ta korist je bila v prisotna predvsem zaradi statistično pomembnega zmanjšanja incidence MI [287 (4,6 %) v skupini, zdravljeni s klopidogrelom in z ASA ter 363 (5,8 %) v skupini z ASA].
By preventing this clumping in some types of blood vessels (called arteries), antiplatelet medicinal products reduce the chances of blood clots forming (a process called atherothrombosis).
S preprečevanjem tega zlepljanja v nekaterih vrstah krvnih žil (imenovane arterije), zaviralci agregacije trombocitov zmanjšajo možnost nastanka krvnih strdkov (proces se imenuje aterotromboza).
For the treatment of this condition your doctor may have placed a stent in the blocked or narrowed artery to restore effective blood flow.
Morda vam je zdravnik za zdravljenje vaše bolezni v zamašeno ali zoženo arterijo namestil žilno opornico, da se obnovi ustrezen pretok krvi.
Following therapeutic doses, approximately 10% is found excreted in the urine as salicylic acid, 75% as salicyluric acid, 10% phenolic- and 5% acyl-glucuronides of salicylic acid.
Po terapevtskih odmerkih se približno 10 % izloči v urinu kot salicilna kislina, 75 % kot salicilurična kislina, 10 % kot fenolni glukuronid in 5 % kot acilglukuronid salicilne kisline.
Clopidogrel and the main circulating (inactive) metabolite bind reversibly in vitro to human plasma proteins (98% and 94% respectively).
Klopidogrel in glavni krožeči (neaktivni) presnovek se in vitro reverzibilno vežeta na humane plazemske proteine (98 % oziroma 94 %).
The population included 27.8% women, 58.4% patients ≥60 years (26% ≥70 years) and 54.5% patients who received fibrinolytics.
Populacijo bolnikov je sestavljalo 27,8 % žensk, 58,4 % bolnikov starosti ≥ 60 let (26 % ≥ 70 let ) in 54,5 % bolnikov, ki so dobivali fibrinolitike.
You should specifically tell your doctor if you take
Obvestite svojega zdravnika, zlasti, če jemljete:
Apart from the specific medicinal product interaction information described above, interaction studies with the combination of clopidogrel/acetylsalicylic acid and some medicinal products commonly administered in patients with atherothrombotic disease have not been performed.
Razen zgoraj navedenih informacij o specifičnih interakcijah z zdravili, študije o interakcijah kombinacije klopidogrela/acetilsalicilne kisline in nekaterih zdravil, ki jih pogosto uporabljajo bolniki z aterotrombotično boleznijo niso bile izvedene.
In cases of confirmed isolated activated Partial Thromboplastin Time (aPTT) prolongation with or without bleeding, acquired haemophilia should be considered.
V primeru podaljšanega potrjenega izoliranega aktiviranega parcialnega tromboplastinskega časa (aPTT), s krvavitvijo ali brez nje, je treba razmisliti o možnosti pojava pridobljene hemofilije.
Patients who have had developed a previous allergic reaction and/or haematological reaction to one thienopyridine may have an increased risk of developing the same or another reaction to another thienopyridine.
Bolniki, ki so kdaj imeli alergijsko in/ali hematološko reakcijo na enega od tienopiridinov, imajo lahko večje tveganje za pojav enake ali druge reakcije na drug tienopiridin.
Patients were required to have either ECG changes compatible with new ischaemia or elevated cardiac enzymes or troponin I or T to at least twice the upper limit of normal.
Bolniki so morali imeti bodisi spremembe elektrokardiograma (EKG), združljive z novo ishemijo ali povišane srčne encime ali troponin I ali T, in sicer najmanj dvakrat nad zgornjo mejo normalnega.
Absorption is at least 50%, based on urinary excretion of clopidogrel metabolites.
Absorpcija je najmanj 50 %, na podlagi presnovkov klopidrogela, izločenih z urinom.
TEVA UK Limited BRAMPTON ROAD HAMPDEN PARK EASTBOURNE, EAST SUSSEX,BN22 9AG, United Kingdom
TEVA UK Limited BRAMPTON ROAD HAMPDEN PARK EASTBOURNE, EAST SUSSEX,BN22 9AG, Velika Britanija
A pharmacodynamic interaction between the combination of clopidogrel/acetylsalicylic acid and heparin is possible, leading to increased risk of bleeding.
Farmakodinamična interakcija med kombinacijo klopidogrela/acetilsalicilne kisline in heparinom je možna in vodi do povečanega tveganja za krvavitev.
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Vendar pa so bile opravljene številne retrospektivne analize za oceno tega učinka pri bolnikih, zdravljenih s klopidogrelom, za katere so na voljo rezultati genotipizacije: CURE (n=2.721), CHARISMA (n=2.428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1.477) in ACTIVE-A (n=601), poleg tega pa tudi številne objavljene kohortne študije.
The following symptoms can also arise: hyperthermia and perspiration, leading to dehydration, restlessness, convulsions, hallucinations and hypoglycaemia.
Pojavijo se lahko tudi sledeči simptomi: hipertermija in znojenje, ki povzroči dehidracijo, nemir, konvulzije, halucinacije in hipoglikemija.
In CHARISMA and one cohort study (Simon), an increased event rate was observed only in poor metabolisers when compared to extensive metabolisers.
V študiji CHARISMA in eni kohortni študiji (Simon) so večji delež dogodkov ugotovili samo pri slabih metabolizatorjih v primerjavi z obsežnimi.
• signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots, and/or confusion (see section 2 ‘Warnings and precautions').
• znaki jetrnih težav, kot je porumenelost kože in/ali oči (zlatenica), ki so lahko, ali pa ne, povezani s krvavitvijo, ki se pojavi pod kožo kot drobne rdeče pike in/ali zmedenostjo (glejte poglavje 2 »Opozorila in previdnostni ukrepi«).
There is a possible association between acetylsalicylic acid (ASA) and Reye's Syndrome when products containing ASA are given to children or adolescents with a viral infection.
Obstaja možna povezava med acetilsalicilno kislino (ASA) in Reyevim sindromom, če otroci ali mladostniki prejemajo zdravila z ASA pri virusni okužbi.
• sudden life-threatening allergic reactions
• nenadne smrtno nevarne alergijske reakcije,
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation.
Zmanjšanje je bilo povezano z 39 % (začetni odmerek) oz. 21 % (vzdrževalni odmerek) zmanjšanjem zaviranja agregacije trombocitov.
If patients must temporarily stop antiplatelet therapy, the combination of clopidogrel/acetylsalicylic acid should be discontinued 7 days prior to surgery.
Če mora bolnik začasno prekiniti zdravljenje z antiagregacijskimi zdravili, je treba kombinacijo klopidogrela/acetilsalicilne kisline prenehati jemati 7 dni pred kirurškim posegom.
Platelet aggregation and bleeding time gradually returned to baseline values, generally within 5 days after treatment was discontinued.
Agregacija trombocitov in čas krvavitve sta se postopoma vrnila na izhodiščno vrednost, običajno v 5 dneh po ukinitvi zdravljenja.
The clinical relevance of this interaction is uncertain.
Klinični pomen te interakcije ni popolnoma znan.
Thrombotic Thrombocytopenic Purpura (TTP) has been reported very rarely following the use of clopidogrel, sometimes after a short exposure.
Zelo redko so poročali o trombotični trombocitopenični purpuri (TTP) po uporabi klopidogrela, ki se je včasih pojavila že po kratki izpostavljenosti.
5.2 Pharmacokinetic properties Clopidogrel:
5.2 Farmakokinetične lastnosti Klopidogrel:
The safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Varnost sočasne uporabe klopidogrela, fibrinsko specifičnih ali fibrinsko nespecifičnih trombolitikov in heparinov je bila ocenjena pri bolnikih z akutnim miokardnim infarktom.
a planned surgery (including dental) in the next seven days.
nedaven kirurški poseg (vključno z zobozdravstvenimi posegi), načrtovan kirurški poseg (vključno z zobozdravstvenimi posegi) v naslednjih sedmih
• skin allergy
• kožna alergija,
Acetylsalicylic Acid: Single-dose studies have shown that the oral toxicity of ASA is low.
Acetilsalicilna kislina: Študije enkratnih odmerkov so pokazale, da je peroralna toksičnost ASA majhna.
Other medicines and Clopidogrel/Acetylsalicylic acid Teva Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Druga zdravila in zdravilo Klopidogrel/acetilsalicilna kislina Teva Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, vključno s tistimi, ki ste jih dobili brez recepta.
Adverse reactions that occurred with clopidogrel alone, with ASA alone* or with clopidogrel in combination with ASA either during clinical studies or that were spontaneously reported are presented in the table below.
Neželeni učinki, zabeleženi samo s klopidogrelom, samo z ASA ali s klopidogrelom v kombinaciji z ASA v kliničnih študijah ali opisani spontano, so navedeni v spodnji tabeli.
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk.
Specifične farmakokinetične študije, izvedene z radioaktivno označenim klopidogrelom, so pokazale, da se matična spojina ali njeni presnovki izločajo v mleko.
In one study, when a single dose of ibuprofen 400 mg was taken within 8 hours before or within 30 minutes after immediate release aspirin dosing (81 mg), a decreased effect of ASA on the formation of thromboxane or platelet aggregation occurred.
V eni študiji, v kateri je bil en enkraten odmerek 400 mg ibuprofena uporabljen v 8 urah pred ali v 30 minutah po zaužitju aspirina s takojšnjim sproščanjem (81 mg), se je zmanjšal učinek acetilsalicilne kisline na nastajanje tromboksana ali agregacijo trombocitov.
Other interactions with clopidogrel and ASA
Druge interakcije s klopidogrelom in z ASA
Hearing loss* or tinnitus*
Poslabšanje sluha* ali tinitus*
Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy.
Podatki epidemioloških študij kažejo večje tveganje za spontani splav, malformacije srca in gastroshize po uporabi zaviralcev sinteze prostaglandinov v zgodnji nosečnosti.
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel.
Če je potrebna takojšnja korekcija podaljšanega časa krvavitve, lahko učinke klopidogrela odpravi transfuzija trombocitov.
Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Germany
Merckle GmbH Ludwig-Merckle-Straße 3 89143 Blaubeuren Nemčija
In CURE, 823 (6.6%) patients received concomitant GPIIb/IIIa receptor antagonist therapy.
V študiji CURE je 823 (6,6 %) bolnikov sočasno prejemalo tudi antagoniste receptorjev glikoproteinov IIb/IIIa.
Due to the presence of both components of the medicinal product, Clopidogrel/Acetylsalicylic acid Teva is contraindicated in case of:
Zaradi vsebnosti obeh učinkovin v zdravilu, je zdravilo Klopidogrel/acetilsalicilna kislina Teva kontraindicirano v primeru:
if you have any stomach or abdominal pain or bleeding in the stomach or bowels (red
če imate bolečine v želodcu ali trebuhu ali krvavitev v želodec ali črevo (rdeče blato ali
Some other medicines may influence the use of Clopidogrel/Acetylsalicylic acid Teva or vice versa.
Nekatera druga zdravila lahko vplivajo na uporabo zdravila Klopidogrel/acetilsalicilna kislina Teva in obratno.
If the use of the combination of clopidogrel/acetylsalicylic acid is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
V primeru prenehanja uporabe kombinacije klopidogrela/acetilsalicilne kisline lahko bolniku koristi nadaljevanje uporabe enega antiagregacijskega zdravila.
For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern.
Pri manjših urezninah ali poškodbah, npr. če se urežete pri britju, navadno ni razloga za skrb.
In patients with recent transient ischaemic attack or stroke who are at high risk of recurrent ischaemic events, the combination of ASA and clopidogrel has been shown to increase major bleeding.
Pri bolnikih z nedavnimi tranzitornimi ishemičnimi atakami ali možgansko kapjo, pri katerih obstaja nevarnost ponavljajočih se ishemij, je dokazano, da kombinacija ASA in klopidogrela poveča hudo krvavitev.
At high ASA doses, the elimination of salicylic acid follows zero-order kinetics (i.e., the rate of elimination is constant in relation to plasma concentration), with an apparent half-life of 6 hours or higher.
Pri velikih odmerkih ASA poteka odstranjevanje salicilne kisline s kinetiko ničelnega reda (tj. delež odstranjevanja je konstanten glede na koncentracijo v plazmi), navidezni razpolovni čas pa je 6 ur ali več.
New cardiovascular events (primary endpoint) were prevented, with relative risk reductions of 22% (CI: 8.6, 33.4), 32% (CI: 12.8, 46.4), 4% (CI: -26.9, 26.7), 6% (CI: -33.5, 34.3) and 14% (CI: -31.6, 44.2), during the 0-1, 1-3, 3-6, 6-9 and 9-12 month study intervals, respectively.
Nove srčnožilne dogodke (primarni opazovani dogodek) so preprečili z zmanjšanjem relativnega tveganja v višini 22 % (IZ: 8,6; 33,4), 32 % (IZ: 12,8; 46,4), 4 % (IZ: -26,9; 26,7), 6 % (IZ: -33,5; 34,3) in 14 % (IZ: -31,6; 44,2) tekom 0-1, 1-3, 3-6, 6-9 oziroma 9-12 mesečnimi intervali študije.
Until the 24th amenorrhea week (5th month of pregnancy), acetylsalicylic acid should not be given unless clearly necessary.
Do 24. tedna amenoreje (5. mesec nosečnosti) se acetilsalicilne kisline ne sme uporabljati, če ni nujno potrebno.
Merckle GmbH Ludwig-Merckle-Strasse 3 D-89143 Blaubeuren-Weiler Germany
Merckle GmbH Ludwig-Merckle-Strasse 3 D-89143 Blaubeuren-Weiler Nemčija
For patients who did not undergo angiography, the primary endpoint was death or recurrent myocardial infarction by Day 8 or by hospital discharge.
Pri bolnikih, pri katerih ni bila opravljena angiografija, sta bila primarna opazovana dogodka smrt ali ponovni miokardni infarkt do 8. dneva oziroma do odpusta iz bolnice.
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, laponsko obliko zmanjšane aktivnosti laktaze ali malabsorpcijo glukoze/galaktoze tega zdravila ne smejo jemati.
If you stop taking Clopidogrel/Acetylsalicylic acid Teva Do not stop the treatment unless your doctor tells you so.
Če ste prenehali jemati zdravilo Klopidogrel/acetilsalicilna kislina Teva Ne prekinite zdravljenja, razen če vam tega ne odredi zdravnik.
It is unknown whether clopidogrel is excreted in human breast milk.
Ni znano, ali se klopidogrel izloča v materino mleko pri človeku.
In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and naproxen increased occult gastrointestinal blood loss.
V klinični študiji pri zdravih prostovoljcih je sočasna uporaba klopidogrela in naproksena povečala okultno izgubo krvi iz prebavil.
Because the active metabolite is formed by CYP450 enzymes, some of which are polymorphic or subject to inhibition by other medicinal products, not all patients will have adequate platelet inhibition.
Ker aktivni presnovek nastane z delovanjem encimov CYP450, med katerimi so nekateri polimorfni ali podvrženi zavrtju z drugimi zdravili, zavrtje trombocitov pri vseh bolnikih ne bo zadostno.
Clopidogrel: During non-clinical studies in rat and baboon, the most frequently observed effects were liver changes.
Klopidogrel: V predkliničnih študijah na podganah in pavijanih, so bile jetrne spremembe najpogosteje opaženi učinek.
In CAPRIE, in patients treated with either clopidogrel or ASA, the overall incidence of any bleeding was 9.3%.
V študiji CAPRIE je bila pri bolnikih, zdravljenih ali s klopidogrelom ali z ASA, celokupna incidenca kakršnihkoli krvavitev 9,3 %.
EXP After first opening bottle use within 30 days.
EXP Porabiti v 30 dneh po prvem odprtju plastenke.
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen.
Poleg tega je bilo IPA 32 % (24 ur) in 61 % (5. dan), kar je več kot pri slabih metabolizatorjih, ki so prejemali shemo 300 mg/75 mg in podobno kot pri drugih metabolizatorskih skupinah s CYP2C19, ki so prejemale shemo 300 mg/75 mg.
This benefit was consistent across age, gender and with or without fibrinolytics, and was observed as early as 24 hours.
Ta koristni učinek je bil prisoten pri vseh starostih, obeh spolih, ob uporabi ali o neuporabi fibrinolitikov, opažen pa je bil že po 24 urah.
5.1 Pharmacodynamic properties Pharmacotherapeutic group: platelet aggregation inhibitors excl. Heparin, ATC Code: B01AC30.
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: zaviralci agregacije trombocitov brez heparina; oznaka ATC: B01AC30